QPPV.COM KNOWLEDGE ASSESSMENT

Buspirone: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Buspirone: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 How should a pharmacovigilance professional weigh an historical account of buspirone's discovery written by a scientist affiliated with the originating company?
Question 2 of 10 Which description best distinguishes buspirone's pharmacology from that of benzodiazepines?
Question 3 of 10 A case report attributes a clinical effect specifically to the active metabolite 1-PP. Which statement best reflects the evidence described in the article?
Question 4 of 10 Two UK generic buspirone SmPCs state different maximum daily doses. What is the most appropriate regulatory response?
Question 5 of 10 A pooled analysis found improvement in anxiety outcomes among patients with GAD, including participants with depressive symptoms. What conclusion is best supported?
Question 6 of 10 During aggregate review, several reports of dizziness are identified, including reports involving CYP3A4 inhibitors. Which approach is most appropriate?
Question 7 of 10 A patient reports no improvement after several initial doses of buspirone. Before classifying the case as pharmacological failure, what is most important to establish?
Question 8 of 10 Which organ-function interpretation is most consistent with the article?
Question 9 of 10 In assessing a suspected interaction, why is a dated medication history more informative than a medication list recorded only at the time of reporting?
Question 10 of 10 A patient reports anxiety after stopping buspirone. Which conclusion is best supported without further case details?

Select an answer to continue.

QPPV.com